The Data Is Genuinely Strong

It is worth being straight about this, because dismissing retatrutide as hype would be inaccurate and would not help anyone decide anything. Eli Lilly's triple agonist — it acts at the GLP-1, GIP and glucagon receptors — has now reported four Phase 3 trials, and the numbers are the largest published in this class.

• ▪TRIUMPH-1 (announced 21 May 2026, 2,339 participants): mean weight loss at 80 weeks of 17.6% on 4mg, 23.7% on 9mg and 25.0% on 12mg, against 3.9% on placebo. Participants escalated to their maximum tolerated dose reached up to 30% at 104 weeks.
• ▪TRIUMPH-2 (23 July 2026, 1,152 patients with obesity and type 2 diabetes): up to 20.8% weight loss and up to 1.6 percentage points of HbA1c reduction at 80 weeks.
• ▪TRIUMPH-3 (1,949 patients with obesity and established cardiovascular disease): up to 22.6% weight loss at 80 weeks.
• ▪TRIUMPH-4 (reported December 2025, obesity with knee osteoarthritis): an average of 28.7% at 68 weeks on 12mg.

The tolerability profile is what you would expect of a potent incretin drug, and at the top dose it is not gentle. In TRIUMPH-1 at 12mg, nausea affected 42.4% of participants, diarrhoea 32.0%, constipation 26.1% and vomiting 25.3%, with dysesthesia and urinary tract infections around 10% each, generally mild to moderate. Discontinuation for adverse events ran at 11.3% against 4.9% on placebo.

Regulatory submission is still pending and approval is not anticipated before 2027 at the earliest. That is the gap the grey market is selling into.

But There Is No Lawful Way to Compound It

This is the part that tends to get skipped, and it is not a technicality. The exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act that let compounding pharmacies and outsourcing facilities operate at all depend on the bulk drug substance qualifying. A substance generally has to be a component of an FDA-approved drug product, be the subject of a USP or National Formulary monograph, or appear on the relevant FDA bulks list.

Retatrutide satisfies none of those, and it is not a close call:

• ▪It is not FDA-approved for any indication.
• ▪It is not a component of any FDA-approved drug product.
• ▪It has no USP or National Formulary monograph.
• ▪It does not appear on the FDA's 503A or 503B bulk drug substances lists.
• ▪It was never placed on an FDA shortage list — so the temporary route that applied to semaglutide and tirzepatide during their shortages, and which ended in 2025, never applied to retatrutide at all.

What the Grey Market Actually Looks Like

Two details tell you most of what you need to know about how this trade sees itself. The first is that the FDA has reported retatrutide being sold under coded names rather than its own — GLP1-R, GLP1-S, GLP1-T. Legitimate medicines are not sold under aliases. The second is that enforcement has not stopped it: warning letters have gone to retatrutide vendors since December 2024, and reporting in 2026 found that most of the companies written to were still advertising.

State boards have moved where the FDA has been slower. The Ohio Board of Pharmacy found that a Florida pharmacy had dispensed 580 non-compliant compounded prescriptions into Ohio between April 2024 and April 2025, of which 153 were retatrutide.

The Other Peptides, and Where They Actually Stand

Retatrutide is usually sold alongside a menu of other compounded peptides, and their status is genuinely more complicated — and currently moving. On 15 April 2026 the FDA announced it would remove twelve peptide bulk substances from Category 2 of its 503A list, the category for substances the agency had determined raise significant safety concerns, because the nominations had been withdrawn.

That was widely read as a green light. It was not. As the regulatory lawyers tracking it put it, removal from Category 2 “does not, by itself, place these substances on the 503A bulks list or into Category 1 for which FDA is exercising enforcement discretion”, and the peptides “will exist in a regulatory gray area until the PCAC meets and the FDA takes final action”. The Pharmacy Compounding Advisory Committee met on 23–24 July 2026 to consider whether BPC-157, KPV, TB-500 and MOTS-c should be added to the 503A bulks list, with further substances scheduled before the end of February 2027.

Read that table for what it is. Some of these substances may well end up on the bulks list; that is what the committee process is for. Until they do, a provider selling them is operating in an area the FDA has explicitly not resolved, and one where the answer could change either way within months.

How Providers Present This

Live Vital is a reasonable worked example, because its disclosure is better than most and it still illustrates the problem. It is a physician-led peptide service operating in all 50 states, with a named prescriber, a free fifteen-minute phone consultation, unlimited messaging and fulfilment through a licensed US pharmacy. Its published prices run from $66 a month for glutathione and $83 for NAD+ through $99 for GHK-Cu, $116 for CJC-1295/ipamorelin or its BPC-157/TB-500 blend, $149 for MOTS-c and its GHK-Cu blends, and $166 for tesamorelin, with retatrutide at $299 a month.

To its credit, its retatrutide page says plainly that the drug is “not FDA-approved for weight management and remains in Phase 3 clinical trials”, and it requires informed consent to that investigational status. That is considerably more honest than services that simply list it as a product. But the same page describes it as “a compounded medication, prescribed off-label”, which — as above — is not what off-label means, and it does not address the fact that there is no lawful compounding pathway. We could not find a published refund policy or stated lab requirements either.

The questions to ask any service offering peptides

• ▪Which pharmacy compounds this, and is it 503A or 503B? A service that will not name it is asking you to trust an anonymous supply chain.
• ▪On what basis is this substance eligible for compounding? For retatrutide there is no good answer to this question.
• ▪What testing is done on the finished product, and can I see a certificate of analysis for my batch?
• ▪What happens if I have an adverse reaction? There is no manufacturer safety surveillance behind an unapproved compounded substance.
• ▪What is the refund policy? If it is not published, get it in writing before paying.

What This Means If You Are On a GLP-1

The honest summary is that you are being offered a better number in exchange for a worse supply chain, and the trade is not currently a good one.

You already have two approved options with large published trial programmes — around 15% of body weight over 68 weeks for semaglutide in STEP 1, and around 21% at 72 weeks for the highest tirzepatide dose in SURMOUNT-1. No head-to-head trial has established that retatrutide outperforms tirzepatide in the same patients; the comparison people make is between separate trials in different populations, which is not the same thing. Meanwhile the approved products come from a named manufacturer, to a known specification, with adverse event reporting attached.

And this wait, unusually, has an end. Four Phase 3 trials have reported and submission is expected. If retatrutide is approved, it will be available with a label, a manufacturer and a supply chain — which is a materially different product from a vial sold today under a code name. If cost is what is driving you toward the grey market, our guides to the cheapest GLP-1 options and programmes under $200 are a better place to start.

Frequently Asked Questions

Where to Go Next

• ▪Brand-name vs compounded GLP-1s — the same regulatory question for the drugs that do have an approved version
• ▪Semaglutide vs tirzepatide — what the approved options actually deliver
• ▪GLP-1 side effects guide — including what the higher-dose tolerability data looks like